Transitioning towards a differentiated TCE platform technology leader, Amino Bio has updated its prospectus.

According to the Zhixun Finance APP, on December 18th, the next-generation multi-antibody pioneer company Anmai Biotechnology updated its prospectus and continued to advance the listing process on the Hong Kong Stock Exchange. The joint lead underwriters are CITIC Securities and CICC.